Rate of response to CyBorD is ‘truly remarkable’
There was a very rapid response [to CyBorD], which has been typical when you incorporate bortezomib into the initial regimens,” commented Dr. Anderson, from the Dana-Farber Cancer Institute in Boston.
There was a very rapid response [to CyBorD], which has been typical when you incorporate bortezomib into the initial regimens,” commented Dr. Anderson, from the Dana-Farber Cancer Institute in Boston.
“As is 100% of the time true, as far as I know, the adverse cytogenetics- del(13) and t(4;14)-are no longer relevant in the context of bortezomib- containing initial therapies.” The rate of complete or near-complete response increased from 39% to 46% to 72%, going from the intent-to-treat population to patients who completed treatment to transplant recipients, Dr. Anderson observed, characterizing the rates achieved as “truly remarkable.”
“I believe this is another example of a very active bortezomib-containing new therapy,” he said.
The main article can be found here:
CyBorD combo supports stem cell collection in newly diagnosed multiple myeloma
!["[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F8987adec8367653dbaf8fc0f82c7dbfcb914281e-500x404.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy,\" according to the study authors.")
